You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD, LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo syndrome mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is presently no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which pla ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle

    SBC: CytoInformatics LLC            Topic: NIA

    DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Image guided Planning System for Skull Correction in Children with Craniosynostosis Phase II

    SBC: Kitware, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in live births It results in cranial malformation that can lead to elevated intra cranial pressure brain growth impairment and developmental deficiency The most common treatment option for craniosynostosis is surgery Currently surgical treatment planning of c ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications

    SBC: GENECAPTURE            Topic: CBD15C001

    The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula

    STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  6. Macromolecule Crystallization Screening Results Analysis

    SBC: IXPRESSGENES, INC.            Topic: 100

    Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Pre Clinical Safety and Efficacy of TRB N for the Treatment of Periodontal Disease

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIDCR

    PROJECT SUMMARY ABSTRACT Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a proprietary chemic ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Screening the Ribosome for New Target Sites

    SBC: NUBAD, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways

    SBC: Abcombi Biosciences Inc            Topic: NIAID

    PROJECT SUMMARY Antiviral drugs are a crucial countermeasure for influenza A virus IAV particularly in circumstances of increased IAV incidence or if a vaccine is unavailable e g virulent H N IAV However the emergence of IAV strains that are resistant to current antivirals H N underscores the need for new treatment strategies particularly those that modify the host response IAVs ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government